Robert E. Winkler
Keine laufenden Positionen mehr
Karriereverlauf von Robert E. Winkler
Ehemalige bekannte Positionen von Robert E. Winkler
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ZENTALIS PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.11.2018 | 19.03.2020 |
| AMICUS THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 06.09.2011 | 01.09.2013 |
| ARRAY TECHNOLOGIES, INC. | Technik-/Wissenschafts-/F&E-Leiter | 19.05.2014 | - |
Ausbildung von Robert E. Winkler
| The Hebrew University Hadassah Medical School | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 4 |
| Israel | 2 |
Operativ
| Chief Tech/Sci/R&D Officer | 3 |
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| AMICUS THERAPEUTICS, INC. | Health Technology |
| ZENTALIS PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Array BioPharma, Inc.
 Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
- Börse
- Insiders
- Robert E. Winkler
- Erfahrung
